


EMLc

ATC codes: [L01AX04](#)

Indication	Hodgkin lymphoma <span style="background-color: #00a651; color: white; padding: 2px;">ICD11 code: 2C10.Z</span>
INN	Dacarbazine
Medicine type	Chemical agent
List type	Complementary (EML) (EMLc)
Formulations	Parenteral > General injections > IV: 100 mg in vial powder for injection ; 200 mg in vial powder for injection
EML status history	First added in 1989 ( <a href="#">TRS 796</a> ) Changed in 2002 ( <a href="#">TRS 914</a> ) Changed in 2007 ( <a href="#">TRS 950</a> ) Changed in 2011 ( <a href="#">TRS 965</a> ) Changed in 2015 ( <a href="#">TRS 994</a> ) Changed in 2023 ( <a href="#">TRS 1049</a> )
Sex	All
Age	Also recommended for children
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 


Tags

Cancer

Wikipedia

[Dacarbazine](#) 

DrugBank

[Dacarbazine](#) 

## Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the inclusion of an additional strength formulation of dacarbazine powder for injection (200 mg in vial) to the EML and EMLc.

[Expert Committee report](#) 

